Form 4: Cryo Cell International Executive Acquires Shares and Options
SEC Form 4 Filing
Oleg Mikulinsky, Chief Information Officer of Cryo Cell International, acquired 20,000 shares and 20,000 stock options through transactions on November 12, 2024.
Summary
- Oleg Mikulinsky, the Chief Information Officer of Cryo Cell International, has reported changes in his beneficial ownership of the company's securities.
- On November 12, 2024, Mr. Mikulinsky acquired 10,000 shares of common stock at $3.20 per share and another 10,000 shares at $4.34 per share.
- He also acquired 10,000 stock options with an exercise price of $3.20 and another 10,000 stock options with an exercise price of $4.34.
- Following these transactions, Mr. Mikulinsky directly owns 104,349 shares of common stock.
- He also holds various stock options with different exercise prices and vesting schedules.
Sentiment
Score: 6
Explanation: The document reflects standard insider trading activity, which is neither particularly positive nor negative. It indicates confidence from the executive but is not a major market-moving event.
Positives
- The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.
- The exercise of stock options at different prices suggests a long-term commitment from the executive.
Industry Context
This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
- The vesting schedules of the stock options are typical for executive compensation packages, often including time-based and performance-based vesting conditions.
- The reported transactions are similar to those of other executives in comparable companies, where stock options and share acquisitions are common forms of compensation.
Stakeholder Impact
- The transactions may have a minor positive impact on shareholder sentiment, as it indicates confidence from a company executive.
- The transactions do not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 04/18/2016 | Date of stock option grant with an expiration date of 04/18/2026 and an exercise price of $3.20. |
| 01/03/2023 | Date of stock option grant with an expiration date of 01/03/2028 and an exercise price of $4.34. |
| 05/21/2018 | Date of stock option grant with an expiration date of 05/21/2028 and an exercise price of $7.49. |
| 09/04/2019 | Date of stock option grant with an expiration date of 09/04/2029 and an exercise price of $7.13. |
| 02/27/2020 | Date of stock option grant with an expiration date of 02/27/2030 and an exercise price of $6.55. |
| 09/23/2021 | Date of stock option grant with an expiration date of 09/23/2028 and an exercise price of $8.00. Vesting commences on this date. |
| 12/28/2021 | Date of stock option grant with an expiration date of 12/28/2028 and an exercise price of $11.90. Vesting is immediate if the stock price reaches $25.00. |
| 12/22/2023 | Date of stock option grant with an expiration date of 12/22/2028 and an exercise price of $5.88. Vesting occurs in three tranches. |
| 11/12/2024 | Date of the reported transactions: acquisition of shares and stock options. |
| 11/14/2024 | Date of the filing of the Form 4. |
Keywords
stock options, share acquisition, beneficial ownership, insider trading, executive compensation, Cryo Cell International, CCEL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.